What did @zacsmithfitness actually say?
The video runs through a tiered ranking of testosterone and fat-loss approaches, framing each as bad, good, or great. The argument: injecting testosterone once weekly is bad, three times weekly is good, and daily injections are great. On compounds, testosterone enanthate is good but "testosterone Cipunate daily" is great. For fat loss, a fat burner is bad, a "redder" (almost certainly Tirzepatide) is good, and combining it with "mott's sea" (likely semaglutide) is the top tier. The video closes with a blood work recommendation, saying a full comprehensive panel beats a basic one, which beats nothing at all.
This is a rapid-fire hierarchy video common in fitness TikTok. The creator is pitching a peptide guide in the caption, so the framing is designed to move an audience toward more aggressive, higher-intervention approaches. That context matters when you're evaluating the enthusiasm behind the rankings.
Does the science back this up?
The injection frequency argument has real pharmacokinetic logic behind it, but the blanket claim that daily is always great is an oversimplification. The GLP-1 receptor agonist stacking claim is where this video gets genuinely problematic from a safety standpoint.
On testosterone injection frequency, the pharmacokinetics are well-documented. Testosterone enanthate has a half-life of roughly 4.5 days, meaning once-weekly dosing produces larger peaks and troughs compared to more frequent administration. A study by Rahnema et al. (2014, Fertility and Sterility) confirmed that stable serum testosterone levels correlate with better symptom management and reduced side effect variability. More frequent dosing smooths those fluctuations. That part checks out.
On combining tirzepatide and semaglutide, there is currently no peer-reviewed clinical evidence supporting dual GLP-1/GIP agonist stacking in humans for safety or efficacy. Tirzepatide already acts on both GIP and GLP-1 receptors. Adding semaglutide on top is not an established clinical protocol, and the additive risk of nausea, pancreatitis, and cardiovascular strain has not been studied in combination use. The creator presents this stack as simply "great" with no caveats.
What did they get wrong (or right)?
The injection frequency hierarchy is directionally right but oversold. Daily testosterone injections require subcutaneous administration and precise dosing discipline. For many patients, three-times-weekly injections achieve clinically equivalent serum stability. A 2020 review by Grech et al. (Journal of Clinical Medicine) found no significant outcome difference between daily subcutaneous and twice or three-times-weekly protocols when total weekly dose was controlled. Calling daily universally "great" ignores patient adherence, injection site tolerance, and individual pharmacokinetics.
The blood work recommendation is the cleanest take in the video. Getting a full comprehensive panel over a basic one is genuinely good advice for anyone on hormonal therapy. Basic panels often miss key markers like SHBG, estradiol, hematocrit, and PSA that matter clinically. That ranking is accurate.
The fat-loss tier list is the most irresponsible segment. Presenting a tirzepatide-plus-semaglutide stack as simply the "great" option, without any discussion of contraindications, prescriber involvement, or documented risk, is not fitness advice. It is an unsupervised polypharmacy recommendation dressed up as a hierarchy.
What should you actually know?
Testosterone administration frequency is a clinical decision, not a universal ranking. Your half-life, your injection tolerance, your lifestyle, and your lab values all factor in. Three-times-weekly and daily protocols both have evidence behind them, and neither is universally superior without knowing the individual patient.
GLP-1 receptor agonists like semaglutide and tirzepatide are prescription medications with real side effect profiles. Tirzepatide (Mounjaro/Zepbound) already has dual GLP-1 and GIP activity built into its mechanism. Stacking it with semaglutide is not a validated clinical approach. The FDA has not approved any such combination, and the combination has not been studied in randomized controlled trials for safety. Anyone presenting this stack as a straightforward upgrade is not giving you the full picture.
Blood work is genuinely non-negotiable if you are using any of these compounds. A comprehensive panel should include a complete metabolic panel, CBC, lipids, estradiol, SHBG, LH, FSH, PSA if applicable, and thyroid markers at minimum. That recommendation from the video is sound, even if everything around it is not.